Canaccord Genuity maintains a Buy rating on Onyx Pharmaceuticals (Nasdaq: ONXX) following strong Q2 results issued Thursday night, continuing to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE